Global News

Mylan to acquire Renaissance’s Specialty and Generics Business for $1B

Monday, May 16, 2016

Mylan has announced an agreement to acquire the non-sterile, topicals-focused specialty and generics business of Renaissance Acquisition Holdings for $950 million in cash at closing, plus additional contingent payments of up to $50 million, subject to customary adjustments. The transaction is expected to be immediately accretive to Mylan’s adjusted diluted earnings per share upon closing.

[Read More]

ICON, Pfizer named Clinical Research Team of the Year

Monday, May 16, 2016

ICONa global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, has announced that, together with Pfizer, it has won the Clinical Research Team of the Year award at the inaugural Clinical and Research Excellence (CARE) Awards.

[Read More]

Can clinical trials be reinvented?

Monday, May 16, 2016

The Pulse on Site Success by Christophe Berthoux

Over the last few years, I have been involved in several initiatives related to strengthening the sustainability and reducing the burden of sites around the globe. This momentum is growing through associations working on behalf of sites such as the Alliance for Clinical Research Excellence and Safety (ACRES), the Association of Clinical Research Professionals (ACRP), the Society of Clinical Research Sites (SCRS), the Collaborative Institutional Training Initiative (CITI), TransCelerate and others.

[Read More]

Melinta’s Baxdela releases positive phase III results for hospital-treated skin infections

Friday, May 13, 2016

Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, today announced top-line results from the second phase III study (RX-3341-303 NCT01984684) of Baxdela (delafloxacin), an investigational anionic quinolone in development for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI).

[Read More]